Lakewood-Amedex updates S-1, adds detail on Nu-3 pipeline and Series C conversion mechanics
The company's September 18, 2026 filing registers 4,512,400 more shares tied to Series C Preferred conversion and details its lead antibiotic candidate's trial progress.
SEC filing